Navigation Links
VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
Date:10/5/2007

econd half of 2007. In addition, VioQuest and the U.S. Army are planning to submit a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) in 2007 for Lenocta(TM) for the treatment of leishmaniasis.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. In addition, this press release also includes forward-looking statements regarding the timing, progress and results of the clinical development, regulatory processes, potential clinical trial initiations, potential IND and NDA filings and commercialization efforts of VioQuest's drug development product candidates. These statements are subject to various risks and uncertainties and include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM), VQD-002, and Xyfid(TM) will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 3
'/>"/>

SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 OTC ... Pharmaceuticals Inc., a biotechnology company, on its approval ... previously traded on OTCQX®, the best marketplace for ... Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... the successful execution of its growth strategy and ...
(Date:8/21/2014)... 21, 2014 Ontotext S4 , ... Ontotext . Now the same enterprise hardened ... structured and unstructured data is available to start-ups and ... enterprise technology. Organizations that do not have resources to ... can use S4 since there is no need for ...
(Date:8/20/2014)... Clintrax Global, Inc., a worldwide provider ... Raleigh, NC , recently announced the addition ... of Administration. As Vice President ... including their alignment with company objectives and policies.  ... an HR executive, specializing in needs assessments, customer ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Clintrax Global, Inc. Announces Addition to Executive Team 2Neurotrope To Host Conference Call 2
... , ... , , , ... samples of low cell numbers , , , ... cells have, for example,limited availability, quantity,and lifespan. Using the Agilent,2100 bioanalyzer ...
... , , , ... , , , , ... Agilent 2100 bioanalyzer can,be used to analyze apoptotic cell samples. Performance ... compared to,those obtained with a conventional flow cytometer. Histogram quality,of the ...
... , , , , ... The In Situ Cell Death Detection Kit has been designed as a precise, fast, and simple, ... the single-cell level in tissues. It is based on the so-called TUNEL, ... , , , , ...
Cached Biology Technology:Flow cytometric analysis of human,primary cells using the Agilent 2100,bioanalyzer and on-chip staining 2Flow cytometric analysis of human,primary cells using the Agilent 2100,bioanalyzer and on-chip staining 3Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 2Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 3Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 4Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 5Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 6Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 7Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 8Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 9In Situ Cell Death Detection Kit 2
(Date:8/20/2014)... University of Tennessee, Knoxville, research finds life can persist ... professor was part of a team that examined waters ... Antarctic ice sheet and found the extreme environment supports ... by Jill Mikucki and her colleagues has implications for ... in the solar system. The findings are published in ...
(Date:8/20/2014)... MA Using population-based screening outcomes of approximately 3 ... including four researchers at the University of Massachusetts Medical ... immunodeficiency (SCID) can be successfully implemented across public health ... published in the Aug. 20 issue of the ... ) showed the rate of SCID in newborns is ...
(Date:8/20/2014)... Ore. -- When are athletes who have suffered concussions ... Oregon study has found that high school athletes who ... 60 days experience a significant regression in their abilities ... The regression, as seen in changes in their balance ... 19 athletes. Ten of the 12 had returned to ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... bioMETRX, Inc., (OTC,Bulletin Board: BMRX), the leading ... that Frank Santamorena, a world,renowned security expert, ... October 21, 2008., Frank Santamorena brings ... level,security expertise. Frank is a consultant to ...
... A UC Davis researcher known for her honey ... with their Old World counterparts to enhance their positive ... and very productive, and hopefully will confer increased resistance ... Susan Cobey. The Carniolan honey bee ( Apis ...
... From stiff plastic limbs and metal rods to complex ... test dummies of yesteryear are evolving and researchers at Wake ... to life. This new generation of human body ... known in research "dummies" before. The models will contain detailed ...
Cached Biology News:bioMETRX, Inc. Welcomes Residential and Commercial Security Expert to Board of Directors 2bioMETRX, Inc. Welcomes Residential and Commercial Security Expert to Board of Directors 3Building a better bee 2Wake Forest plays integral role in effort to revolutionize vehicle safety 2Wake Forest plays integral role in effort to revolutionize vehicle safety 3
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: